AstraZeneca (AZN) said Friday that data from a late-stage trial showed Fasenra significantly delayed the time to first worsening or flare in patients with hypereosinophilic syndrome.

The company said the trial has met its primary endpoint and treatment with Fasenra reduced risk of worsening or flare by 65%, while also improving fatigue symptom relief by week 4 and persisted to week 24.

Fasenra reduced the annualized flare rate by 66% and delayed time to first hematologic relapse, while also meeting all key secondary endpoints, AstraZeneca said.

The trial evaluated a 30 mg subcutaneous injection of Fasenra administered once every four weeks.

Fasenra's safety profile was consistent with earlier studies, the company said.

Price: 84.37, Change: +0.60, Percent Change: +0.72